Last reviewed · How we verify

NEFECON — Competitive Intelligence Brief

NEFECON (NEFECON) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Targeted corticosteroid. Area: Nephrology / Immunology.

phase 3 Targeted corticosteroid Glucocorticoid receptor (local kidney delivery) Nephrology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

NEFECON (NEFECON) — Calliditas Therapeutics AB. Nefecon is a targeted immunosuppressant that delivers budesonide directly to the kidney to reduce inflammation in IgA nephropathy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NEFECON TARGET NEFECON Calliditas Therapeutics AB phase 3 Targeted corticosteroid Glucocorticoid receptor (local kidney delivery)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Targeted corticosteroid class)

  1. Calliditas Therapeutics AB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NEFECON — Competitive Intelligence Brief. https://druglandscape.com/ci/nefecon. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: